Sign up Australia
Proactive Investors - Run By Investors For Investors

BARD1 Life Sciences approaching "important milestone" on path to commercialisation

BARD1 Life Sciences Ltd (ASX:BD1) chief executive Dr Leearne Hinch updates Proactive Investors on the Perth-based medical technology company’s progress in developing and commercialising diagnostics for the early detection, and possibly treatment, of cancer.

"Our company offers quite a broad patent portfolio, which other companies don't necessarily have. We have two cancer tests in the pipeline. We've also got extremely good results across multiple studies validating the accuracy of our two cancer diagnostics, for both lung cancer and ovarian cancer. So, what we offer is a pipeline rather than just one diagnostic test, and importantly our BARD1 biomarkers can actually be applied to multiple cancers, including breast cancer and prostate cancer, and other cancers," says Hinch.

"BARD1 has got a broad patent portfolio which covers BARD1 DNA and protein sequences. It also covers both diagnostic and therapeutic methods across various cancers. During this last quarter, we had both a Japanese and an Israeli provisional patent granted, so that strengthens our portfolio such that we now have eight granted patents across the portfolio and 20 pending patents," Hinch continues.

The company recently completed a capital raising of $1.3 million to strengthen its cash position ahead of the next phase of research and development. Hinch explains, "BARD1's focus now is on moving to the next development stage, which is where we transfer our research assay to a commercial platform. That's a very important milestone for the company.”

 
Meet Hummingbird Resources plc, Danakali Ltd, Avation PLC and Kodal Minerals PLC at our event, London , 20 September 2018. Register here »
View full BD1 profile View Profile

Bard1 Life Sciences Ltd Timeline

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use